Education
About Us
Working with TipRanks
Follow Us
Apimeds Pharmaceuticals US, Inc. (APUS)
:APUS
Total Valuation
Apimeds Pharmaceuticals US, Inc. has a market cap or net worth of $24.52M. The enterprise value is $18.04M.
Market Cap$24.52M
Enterprise Value$18.04M
Share Statistics
Apimeds Pharmaceuticals US, Inc. has 12,575,983 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,575,983
Owned by Insiders64.31%
Owned by Institutions2.18%
Financial Efficiency
Apimeds Pharmaceuticals US, Inc.’s return on equity (ROE) is 1.02 and return on invested capital (ROIC) is 167.49%.
Return on Equity (ROE)1.02
Return on Assets (ROA)-106.46
Return on Invested Capital (ROIC)167.49%
Return on Capital Employed (ROCE)1.26
Revenue Per Employee0.00
Profits Per Employee-695.00K
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Apimeds Pharmaceuticals US, Inc. is ―. Apimeds Pharmaceuticals US, Inc.’s PEG ratio is -0.23.
PE Ratio―
PS Ratio0.00
PB Ratio-18.67
Price to Fair Value-18.67
Price to FCF-34.57
Price to Operating Cash Flow-4.71
PEG Ratio-0.23
Income Statement
In the last 12 months, Apimeds Pharmaceuticals US, Inc. had revenue of 0.00 and earned -1.39M in profits. Earnings per share was -0.12.
Revenue0.00
Gross Profit0.00
Operating Income-1.28M
Pretax Income-1.39M
Net Income-1.39M
EBITDA-1.27M
Earnings Per Share (EPS)-0.12
Cash Flow
In the last 12 months, operating cash flow was -5.21M and capital expenditures -35.91K, giving a free cash flow of -5.24M billion.
Operating Cash Flow-5.21M
Free Cash Flow-5.24M
Free Cash Flow per Share-0.42
Dividends & Yields
Apimeds Pharmaceuticals US, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.89
52-Week Price Change-11.36%
50-Day Moving Average1.68
200-Day Moving Average―
Relative Strength Index (RSI)45.47
Average Volume (3m)104.60K
Important Dates
Apimeds Pharmaceuticals US, Inc. upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Apimeds Pharmaceuticals US, Inc. as a current ratio of 0.01, with Debt / Equity ratio of 6.13%
Current Ratio0.01
Quick Ratio0.01
Debt to Market Cap0.02
Net Debt to EBITDA-0.47
Interest Coverage Ratio-10.83
Taxes
In the past 12 months, Apimeds Pharmaceuticals US, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Apimeds Pharmaceuticals US, Inc. EV to EBITDA ratio is -20.40, with an EV/FCF ratio of -35.38.
EV to Sales0.00
EV to EBITDA-20.40
EV to Free Cash Flow-35.38
EV to Operating Cash Flow-35.38
Balance Sheet
Apimeds Pharmaceuticals US, Inc. has $6.99M in cash and marketable securities with $500.10K in debt, giving a net cash position of $6.49M billion.
Cash & Marketable Securities$6.99M
Total Debt$500.10K
Net Cash$6.49M
Net Cash Per Share$0.52
Tangible Book Value Per Share-$0.12
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Apimeds Pharmaceuticals US, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―